Viewing Study NCT04226261


Ignite Creation Date: 2025-12-24 @ 11:50 AM
Ignite Modification Date: 2025-12-25 @ 11:53 AM
Study NCT ID: NCT04226261
Status: UNKNOWN
Last Update Posted: 2020-01-13
First Post: 2020-01-09
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Next Generation Pathogen Sequencing for Prediction of Infection in Rheumatic Disease
Sponsor:
Organization:

Raw JSON

{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007239', 'term': 'Infections'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Plasma or serum samples collected but not required for clinical care will undergo next generation pathogen sequencing.'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 200}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2020-01-15', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-01', 'completionDateStruct': {'date': '2021-06-15', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2020-01-09', 'studyFirstSubmitDate': '2020-01-09', 'studyFirstSubmitQcDate': '2020-01-09', 'lastUpdatePostDateStruct': {'date': '2020-01-13', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-01-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-01-15', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of NGS-positive results', 'timeFrame': 'Once (within 72 hours of enrollment)', 'description': 'To estimate the sensitivity of next generation pathogen sequencing for prediction of infection, the proportion of NGS-positive results in all positive infection will be given.'}, {'measure': 'Proportion of NGS-negative results', 'timeFrame': 'Once (within 72 hours of enrollment)', 'description': 'To estimate the specificity of next generation pathogen sequencing for prediction of infection, the proportion of NGS-negative results in all negative infection will be given.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Infection']}, 'referencesModule': {'references': [{'pmid': '31855231', 'type': 'BACKGROUND', 'citation': 'Goggin KP, Gonzalez-Pena V, Inaba Y, Allison KJ, Hong DK, Ahmed AA, Hollemon D, Natarajan S, Mahmud O, Kuenzinger W, Youssef S, Brenner A, Maron G, Choi J, Rubnitz JE, Sun Y, Tang L, Wolf J, Gawad C. Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer. JAMA Oncol. 2020 Apr 1;6(4):552-556. doi: 10.1001/jamaoncol.2019.4120.'}], 'seeAlsoLinks': [{'url': 'https://www.clinicaltrials.gov/ct2/show/NCT03226158?id=NCT02505568+OR+NCT02756650+OR+NCT01960790+OR+NCT02648581+OR+NCT02985775+OR+NCT04056533+OR+NCT01185223+OR+NCT03226158&draw=2&rank=2&load=cart', 'label': 'Next Generation Pathogen Sequencing for Prediction of Adverse Events'}]}, 'descriptionModule': {'briefSummary': 'The majority of patients diagnosed with rheumatic disease, such as systemic lupus erythematosus, inflammatory myositis, and vasculitis, will experience fever or infection during their course of therapy. The most common microbiologically documented infection is bacterial, virus, and fungal, which can be associated with the severity and mortality of disease. Current methods of diagnosis require a significant load of pathogen making early detection difficult. Delayed diagnosis and delayed optimal therapy of infection are associated with increased morbidity and mortality.\n\nThis study seeks to identify whether next generation sequencing (NGS) of pathogens can identify patients with infection treated with corticosteroid and immunosuppressive agents. This would enable preemptive targeted therapy to replace prophylaxis treatment which often leads to some adverse events and antibiotic resistance.', 'detailedDescription': 'Plasma/Serum samples collected but not required for clinical care (discarded samples) will be collected and stored. Results of NGS will be compared between patients who develop definite infection immediately (within 72 hours) after sample collection, and those who remain well. Clinical data describing baseline information about the patient and rheumatic diseases, antibiotic and steroid or immunosuppressor therapy exposure, pathogen testing, immunology results, and infection-related events will be collected prospectively from the electronic medical record.\n\nAn initial exploratory phase will examine approximately 50 participants to determine whether the effectiveness of predicting infections. The study may then enroll up to 200 participants to collection additional data for analysis.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '16 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': "Participants who are being treated at Peking University People's Hospital and who have a high risk of infection.", 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* 18 years to 70 years;\n* Undergoing care for rheumatic disease at Peking University People's Hospital;\n* In a category of patients who are considered by the investigator to be at high risk of infection\n\nExclusion Criteria:\n\n* Any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol"}, 'identificationModule': {'nctId': 'NCT04226261', 'briefTitle': 'Next Generation Pathogen Sequencing for Prediction of Infection in Rheumatic Disease', 'organization': {'class': 'OTHER', 'fullName': "Peking University People's Hospital"}, 'officialTitle': 'Prediction of Infection in Patients With Rheumatic Disease at High Risk of Infection', 'orgStudyIdInfo': {'id': 'NGPSPIRD'}}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Zhanguo Li, M.D, Ph.D', 'role': 'CONTACT', 'email': 'li99@bjmu.edu.cn', 'phone': '+8601088324317'}, {'name': 'Jiali Chen, M.D', 'role': 'CONTACT', 'email': 'chenjiali0389@163.com', 'phone': '+8618801206400'}], 'overallOfficials': [{'name': 'Zhanguo Li, M.D, Ph.D', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Peking University People's Hospital"}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Peking University People's Hospital", 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}